Cytodyn Inc (CYDY)

[fred198484]

Thanks! I have seen that above before but that version gave a little more info in the footnotes. Do you know how they define "second line therapy"? I assume a patient on any of the normal 5 classes of drugs is on a first line therapy but perhaps that is not the correct way of thinking about it. I have not been to one of the company's presentations, but have listened into many of Nadar's conference calls and never got the impression they were focusing much on the combo market. But if it is truly a 207,000 patient market they should be making a lot of noise about it. It certainly would help them raise the needed funds. And it makes it all the more difficult to understand why they continue to try to raise money via Paulsen versus one of the larger brokers. IF this is a legit market and they have completed enrollment of their phase III trial with results coming shortly, they should be able to convince a normal investment bank to work with them.